Breaking News Instant updates and real-time market news.

LOXO

Loxo Oncology

$159.49

-3.01 (-1.85%)

13:20
10/07/18
10/07
13:20
10/07/18
13:20

Loxo Oncology announces LOXO-292 durability update in RET-Mutant MTC

Loxo Oncology announced updated interim clinical data for LOXO-292 from the global Phase 1/2 LIBRETTO-001 trial in patients with RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer who were initially included in the LOXO-292 presentation at the 2018 ASCO Annual Meeting. In these 38 patients, approximately 3.5 months of additional patient follow-up were available, as were first follow-up scans for the nine patients most recently enrolled. Sixteen of 17 responding RET-mutant MTC patients remained on therapy, with median follow-up of 8.4 months. Seven of seven responding RET fusion-positive thyroid cancer patients remained on therapy, with median follow-up of 8.5 months. Inclusion of new restaging data for the most recently enrolled patients resulted in a 59% overall response rate in the presented subset of RET-mutant MTC patients, and a 78% confirmed overall response rate in the presented subset of RET fusion-positive thyroid cancer patients. These data were presented at the 88th Annual Meeting of the American Thyroid Association. The data presented were based on a July 19, 2018 data cut-off date and included the 29 patients with RET-mutant MTC and the nine patients with RET fusion-positive thyroid cancer who were initially included in the LOXO-292 presentation at the 2018 ASCO Annual Meeting. Patients were heavily pretreated, having received a median of three prior systemic treatment regimens. Of the patients with RET-mutant MTC, 79% had previously received cabozantinib or vandetanib and 45% had received prior treatment with both agents. Of the patients with RET fusion-positive thyroid cancer, 78% had previously received radioactive iodine and 78% had previously received sorafenib or lenvatinib. Anti-tumor activity was observed regardless of RET mutation, RET fusion partner, and prior multikinase inhibitor treatment. One patient, with RET fusion-positive thyroid cancer, had RECIST target lesions in the central nervous system and exhibited an intracranial partial response by RECIST 1.1, pending confirmation. Of the 82 patients in the safety analysis, most treatment-emergent adverse events were Grade 1 in severity and judged by the investigator as not related to LOXO-292.

  • 19

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO Loxo Oncology
$159.49

-3.01 (-1.85%)

09/17/18
GUGG
09/17/18
INITIATION
Target $184
GUGG
Neutral
Loxo Oncology initiated with a Neutral at Guggenheim
Target $184.
09/24/18
LEER
09/24/18
INITIATION
Target $205
LEER
Outperform
Loxo Oncology initiated with an Outperform at Leerink
Leerink analyst Andrew Berens started Loxo Oncology with an Outperform rating and $205 price target.
09/26/18
PIPR
09/26/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo RET inhibitor still looks superior to Blueprint's, says Piper Jaffray
Loxo Oncology (LOXO) provided an update of the Phase I/II Libretto study of LOXO-292, the company's RET inhibitor and the vast majority of the current valuation, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. While the overall response rate dropped slightly from 77% to 68% in more patients, it still appears superior to Blueprint Medicines' (BPMC) competing BLU-667, which has thus far demonstrated a 47% response rate in a similar patient population, the analyst contends. Van Buren adds that he's unconcerned by the two new grade three adverse events reported. He believes there "may very well" be upside to his current $1.5B peak sales estimate by the mid-2020s. The analyst reiterates an Overweight rating on Loxo Oncology with a $200 price target.
09/26/18
STFL
09/26/18
NO CHANGE
Target $217
STFL
Buy
Loxo data not 'transformational,' but keeps inspiring confidence, says Stifel
Stifel analyst Stephen Willey said the incremental follow-up data from Loxo Oncology's (LOXO) LIBRETTO-001 trial isn't "transformational," but it does confirm his confidence in the establishment of a high competitive hurdle for LOXO-292, which he sees being a "best-in-class" and first-to-market asset in a $1B+ market. He remains confident LOXO-292 is the superior asset, but acknowledges the anticipation of Blueprint Medicines' (BPMC) updated BLU-667 data at some point in late-FY18 to early-FY19 could serve as a bit of headwind on Loxo shares nearer to that data release. Willey keeps a Buy rating and $217 price target on Loxo shares.

TODAY'S FREE FLY STORIES

ZSAN

Zosano Pharma

$4.19

1.98 (89.59%)

11:40
02/21/19
02/21
11:40
02/21/19
11:40
Recommendations
BTIG boosts Zosano target to $19 on 'solid' migraine safety data »

BTIG analyst Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:38
02/21/19
02/21
11:38
02/21/19
11:38
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:38
02/21/19
02/21
11:38
02/21/19
11:38
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

UNIT

Uniti Group

$11.23

-1.035 (-8.44%)

11:35
02/21/19
02/21
11:35
02/21/19
11:35
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 11

    Mar

  • 11

    Mar

ZSAN

Zosano Pharma

$3.89

1.68 (76.02%)

11:32
02/21/19
02/21
11:32
02/21/19
11:32
Hot Stocks
Breaking Hot Stocks news story on Zosano Pharma »

Zosano Pharma jumps 100%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Conference/Events
UBS leisure/lodging analyst to hold an analyst/industry conference call »

Leisure, Gaming &…

ZSAN

Zosano Pharma

$3.89

1.68 (76.02%)

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Hot Stocks
Zosano says Qtrypta long-term study shows 'well-tolerated safety profile' »

Zosano Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYNE

Zynerba

$4.85

-0.05 (-1.02%)

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Hot Stocks
Zynerba patent listed by World Intellectual Property Organization »

The patent listed by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$24.23

-0.45 (-1.82%)

11:25
02/21/19
02/21
11:25
02/21/19
11:25
Options
JD.com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 04

    Mar

  • 20

    Mar

KMTUY

Komatsu

$0.00

(0.00%)

11:21
02/21/19
02/21
11:21
02/21/19
11:21
Downgrade
Komatsu rating change  »

Komatsu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:20
02/21/19
02/21
11:20
02/21/19
11:20
General news
Treasury announced $113 B in shorter dated coupon sales for next week »

Treasury announced $113 B…

SCI

Service Corp.

$42.31

-0.42 (-0.98%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Hot Stocks
Service Corp. raises quarterly cash dividend 6% to 18c per share »

Service Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
02/21/19
02/21
11:16
02/21/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

GS

Goldman Sachs

$197.12

-1.49 (-0.75%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Initiation
Goldman Sachs initiated  »

Odeon's Dick Bove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

  • 12

    Mar

11:10
02/21/19
02/21
11:10
02/21/19
11:10
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

DK

Delek US

$36.95

-0.13 (-0.35%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Options
Delek US draws upside call buyers as shares slip off early highs »

Delek US draws upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
02/21/19
02/21
11:10
02/21/19
11:10
General news
Existing home sales fell 1.2% in January to 4.99 M, a 3-year low »

Existing home sales fell…

11:08
02/21/19
02/21
11:08
02/21/19
11:08
General news
3-Month Bill Announcement CUSIP Number data reported »

3-Month Bill Announcement…

MNST

Monster Beverage

$58.64

-0.07 (-0.12%)

11:07
02/21/19
02/21
11:07
02/21/19
11:07
Options
Monster Beverage option volume spikes to 3X daily average amid active trading »

Monster Beverage option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LIVN

LivaNova

$98.56

-1.32 (-1.32%)

11:07
02/21/19
02/21
11:07
02/21/19
11:07
Recommendations
LivaNova analyst commentary  »

Piper says Japanese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

  • 07

    May

  • 08

    May

  • 09

    May

UBCP

United Bancorp

$10.95

(0.00%)

11:04
02/21/19
02/21
11:04
02/21/19
11:04
Hot Stocks
United Bancorp raises quarterly cash dividend to 13.25c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIVN

LivaNova

$98.59

-1.29 (-1.29%)

11:03
02/21/19
02/21
11:03
02/21/19
11:03
Hot Stocks
LivaNova announces national reimbursement in Japan for Perceval valve for AVD »

LivaNova announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

  • 07

    May

  • 08

    May

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.